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Abstract 
Background: Extracellular acidosis is a condition found within the tumor microenvironment due to inadequate 
blood perfusion, hypoxia, and altered tumor cell metabolism. Acidosis has pleiotropic effects on malignant progres‑
sion; therefore it is essential to understand how acidosis exerts its diverse effects. TDAG8 is a proton‑sensing G‑pro‑
tein‑coupled receptor that can be activated by extracellular acidosis.
Methods: TDAG8 gene expression was analyzed by bioinformatic analyses and quantitative RT‑PCR in human 
hematological malignancies. Retroviral transduction was used to restore TDAG8 expression in U937, Ramos and other 
blood cancer cells. Multiple in vitro and in vivo tumorigenesis and metastasis assays were employed to evaluate the 
effects of TDAG8 expression on blood cancer progression. Western blotting, immunohistochemistry and biochemical 
approaches were applied to elucidate the underlying mechanisms associated with the TDAG8 receptor pathway.
Results: TDAG8 expression is significantly reduced in human blood cancers in comparison to normal blood cells. 
Severe acidosis, pH 6.4, inhibited U937 cancer cell proliferation while mild acidosis, pH 6.9, stimulated its prolifera‑
tion. However, restoring TDAG8 gene expression modulated the U937 cell response to mild extracellular acidosis and 
physiological pH by reducing cell proliferation. Tumor xenograft experiments further revealed that restoring TDAG8 
expression in U937 and Ramos cancer cells reduced tumor growth. It was also shown U937 cells with restored TDAG8 
expression attached less to Matrigel, migrated slower toward a chemoattractant, and metastasized less in severe com‑
bined immunodeficient mice. These effects correlated with a reduction in c‑myc oncogene expression. The mecha‑
nistic investigation indicated that Gα13/Rho signaling arbitrated the TDAG8‑mediated c‑myc oncogene repression in 
response to acidosis.
Conclusions: This study provides data to support the concept that TDAG8 functions as a contextual tumor sup‑
pressor down‑regulated in hematological malignancies and potentiation of the TDAG8 receptor pathway may be 
explored as a potential anti‑tumorigenic approach in blood cancers.
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Background
In the early twentieth century Otto Warburg recog-
nized a metabolic phenomenon that occurred in cancer 
cells, currently known as the Warburg effect [1–4]. 
Warburg discovered cancer cells favor glycolysis rather 
than oxidative phosphorylation for energy production, 
even in the presence of oxygen [1–4]. It was originally 
hypothesized that irreversible injury of mitochondrial 
respiration is the cause of cancer cell formation [1]. 
However, this hypothesis was to some extent discred-
ited as most cancers retain their ability to exploit mito-
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normal cells [5–7]. As a result of unrestricted glycolysis 
the tumor microenvironment is spatially acidic [8–10]. 
Extracellular acidosis has pleiotropic effects on tumor 
growth and cancer progression [10–14]. Tumor acido-
sis can stimulate cell death, reduce cell proliferation, 
and induce chromosomal instability of normal somatic 
cells and cancer cells [13–16]. In addition, tumor cells 
that become resistant to extracellular acidosis have 
been reported more malignant and invasive [17, 18]. 
Therefore, extracellular tumor acidosis augments can-
cer progression in a Darwinian manner worsening 
disease prognosis. As such, it is imperative to under-
stand how tumor cells sense and respond to acidic 
surroundings for adequate comprehension of cancer 
development.
T cell death-associated gene 8 (TDAG8, also known as 
GPR65) is a member of the proton sensing G-protein cou-
pled receptor family, which also includes GPR4, GPR68 
(OGR1), and GPR132 (G2A). The family of G-protein 
coupled receptors is activated by extracellular acidosis, 
which illuminates a receptor signaling connection to the 
acidic conditions found in tumor microenvironment [19]. 
The human TDAG8 gene has been mapped to chromo-
some 14q31-32.1, a location that abnormalities associ-
ated with T cell lymphoma and leukemia are found and is 
primarily expressed in immune cells and leukocyte-rich 
tissues such as circulating peripheral leukocytes, spleen, 
thymus, and tonsils [20, 21]. TDAG8 has been reported 
to have both pro- and anti-oncogenic effects in blood 
cancers, which indicate TDAG8 effects are cell type and 
context dependent [22–24]. Therefore, it is imperative 
to understand the contextual effects of TDAG8 in hema-
tological malignancies. Blood cancer cells are generally 
glycolytic and produce lactic acid that can acidify the 
microenvironment. Some types of hematological malig-
nancies, such as lymphomas, have the ability to form 
solid tumors in which the tumor microenvironment is 
acidic. Other types of hematological malignancies, such 
as leukemia and multiple myeloma, form in and metasta-
size to bone marrow that has hypoxic and possibly acidic 
niches [25, 26]. In rare cases, systemic lactic acidosis 
occurs in patients with hematological malignancies and 
is associated with poor prognosis [27].
In this study the effects of acidosis and TDAG8 gene 
expression was investigated in blood cancers. TDAG8 
gene expression was examined in hematological malig-
nancies revealing a significant reduction in comparison 
to normal immune cells and leukocyte-rich tissues. Func-
tional studies demonstrated that restoration of TDAG8 
gene expression suppressed the growth, migration and 




TDAG8 gene expression was investigated in blood can-
cers using the Oncomine database. A differential analy-
sis of TDAG8 gene expression was performed between 
leukemia, lymphoma, and myeloma datasets and normal 
immune cells and leukocyte-rich tissue. Additional bio-
informatics analyses were performed on datasets from 
the National Center for Biotechnology Information 
(NCBI) Gene Expression Omnibus (GEO). The raw data 
was downloaded using expression console software HG_
u133_Plus_2 and HG_u133a_2 as libraries. The analysis 
was run and the RMA normalization method was used 
to generate the values graphed. The output file was then 
merged with the probe set downloaded from Affymetrix.
Plasmid constructs
The MSCV-huTDAG8-IRES-GFP construct was made 
previously and the empty construct, MSCV-IRES-GFP, 
was used as a control [23]. For the pMSCV-huTDAG8-
IRES-YFP-P2A-OF-LUC construct, the open reading 
frame of human TDAG8 was amplified using primers 
designed to contain the EcoRI and XhoI restriction 
enzyme sites: 5′-ATAAGAATGAA TTCACCATGAAC 
AGCACATGTATTGAAGAA-3′ and 5′-ATAAGAATG 
AATTCCTCGAG CTACTCAAGGACCTCTAATTCC 
AT-3′. The pMSCV-IRES-YFP-P2A-OF-LUC plasmid 
was then digested with EcoRI and XhoI and the huT-
DAG8 open reading frame was cloned into it generat-
ing the pMSCV-huTDAG8-IRES-YFP-P2A-OF-LUC 
construct. The resultant construct was verified by DNA 
sequencing.
Cell lines and culture
All the cancer cell lines were obtained from American 
Type Culture Collection (ATCC) with characterization 
as described in the product sheet. All cell lines were 
cultured in Roswell Park Memorial Institute medium 
(RPMI) supplemented with 10% fetal bovine serum (FBS) 
in a tissue culture incubator set at 37  °C and 5%  CO2. 
RPMI/FBS medium was buffered using 7.5 mM HEPES, 
7.5  mM EPPS and 7.5  mM MES, known collectively as 
RPMI/HEM, as previously described [23]. Cells used for 
experiments were > 95% viable as assessed by the trypan 
blue dye exclusion method.
To generate green fluorescent protein (GFP) and yellow 
fluorescent protein (YFP)/luciferase (Luc) cell lines with 
restored TDAG8 gene expression, retroviral-mediated 
cell transduction was performed as previously described 
[28]. To generate the Gα13 signaling-deficient cell lines 
the p115 Rho RGS construct was subcloned into the 
pQCXIP vector as previously described [28, 29]. The 
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p115 Rho RGS-pQCXIP and empty pQCXIP retroviral 
vectors were then stably transduced into U937 cells.
EdU cell proliferation assay
The Click-iT® Plus EdU Imaging Kit (Thermo Fisher 
Scientific) was used to examine U937/Vector and U937/
TDAG8 cell proliferation. Fluorescence microscopy with 
the  EVOS®fl Digital Inverted Microscope was used to 
take images of cells incorporating  Hoescht® 33,342 dye 
and the EdU analogue, and also images with transmitted 
light in the same field of view at a 200 × magnification. 
Adobe Photoshop’s counting tool was used to count the 
number of total cells according to  Hoescht® 33,342 dye 
and proliferating cells according to EdU positive cells.
Cell growth competition assay
The same number of non-GFP expressing cells (U937/
Parental or RPMI 8226/Parental) and GFP expressing 
cells (Vector or TDAG8) were mixed into a well and the 
percentages of non-GFP and GFP cells were measured 
using flow cytometry over 14 days. Cell population per-
centages were analyzed and graphed.
Annexin V/7AAD staining
Cells were stained with the PE Annexin V Apoptosis 
Detection Kit I (BD Biosciences). Emission of single cell 
fluorescence was measured at 572  nm for Annexin V, 
647 nm for 7AAD, and 525 nm for GFP. The results were 
analyzed with CellQuest software (BD Biosciences).
Quantitative reverse transcription‑polymerase chain 
reaction (RT‑PCR)
Gene expression was determined by quantitative RT-PCR 
as previously described [23], using the following TaqMan 
predesigned primer/probes from Invitrogen, TDAG8 
(Hs00269247_s1), c-myc (Hs00153408_m1), and β-actin 
(Hs99999903_m1). Relative gene expression was calcu-
lated using the  2−ΔΔCt method [30].
Western blotting
Western blot was performed as previously described [23]. 
Antibodies of c-myc (product #5605), phospho-paxillin 
(Y118) (#2541), phospho-CREB (S133) (#9198), CREB 
(#9197), caspase-3 (#9665), caspase-9 (#9502), cleaved 
PARP XP (#5625), and β-actin (#4970) were purchased 
from Cell Signaling Technology.
Histology
Immunohistochemistry (IHC) for antibodies against 
c-myc (Abcam, #ab32072), cleaved PARP (Cell Signal-
ing Technology, #5625), Ki67 (Abcam, #ab15580), and 
human nucleoli (Abcam, #ab190710) was performed 
on paraffin-embedded 5  µm sections. Antigen retrieval 
was performed by boiling slides in TRIS–EDTA + 0.1% 
Tween-20 pH 9.0 antigen retrieval buffer for 10–18 min. 
SuperPicture™ 3rd Gen IHC Detection Kit (Invitrogen) 
was used to complete immunohistochemistry.
Transwell cell migration assays
Two hundred microliter of cells were seeded into the 
transwell insert at 5 ×  106  cells/ml in migration buffer 
consisting of RPMI media buffered to pH 7.4 and pH 6.4 
without FBS and supplemented with 0.1% BSA. Chem-
oattractant (5  ng/mL SDF1-α) was then added into the 
bottom well. The plates were then incubated at 37 °C and 
5%  CO2 for 5 h. After 5 h the number of migrated cells 
was quantified using flow cytometry.
Cell attachment assays
Matrigel solution was added into each well to form a thin 
layer of gel. U937 cells were plated onto Matrigel and 
incubated at 37 °C and 5%  CO2 for 1 h in culture media 
buffered to pH 7.4 or 6.4. After 1 h the media was aspi-
rated and the wells were washed 4 times with RPMI to 
remove non-adherent cells. For the endothelial cell 
attachment assay Human Umbilical Vein Endothelial cells 
(HUVEC) were seeded on 0.1% gelatin-coated plates to 
create a monolayer. Next, U937 cells were plated in each 
well in culture media buffered to pH 7.4 or 6.4. Plates 
were incubated at 37 °C and 5%  CO2 for 1 h. After 1 h the 
media was aspirated and the wells were washed 4 times 
with RPMI. For all attachment assays several images were 
taken in various areas of the well to give an adequate rep-
resentation. Cell attachment was quantified by counting 
every cell in each field of view.
Primary tumor and metastasis xenograft
NOD.CB17-Prkdc<SCID>/J mice were purchased from 
Jackson Laboratories and bred at East Carolina University 
animal facilities for research purposes. All experimental 
procedures were performed according to the NIH guide 
for the care and use of laboratory animals and the insti-
tutional regulations. In each experiment, 5 × 106 U937 or 
Ramos cells were injected into the flanks of SCID mice. 
Tumor growth was measured daily using a caliper. Tail 
vein injections were performed with 2 × 106 U937 cells 
in SCID mice. When mice reached endpoint parameters, 
e.g. lethargy, hunched posture, and unkempt appearance, 
they were euthanized for analysis. The experiment was 
terminated 8 months after injection when the remaining 
mice showed no signs of disease progression. To monitor 
U937-Luc tumor growth in  vivo, intraperitoneal injec-
tion with d-Luciferin (Caliper Life Sciences, Catalogue 
# 119222) at 15 mg/ml in DPBS was performed. Subse-
quently, mice were imaged using the IVIS Lumina XR 
unit.
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Statistical analysis
Statistical analysis was performed using the GraphPad 
Prism software. The unpaired t test was used to test for 
statistical significance between 2 groups. Error bars rep-
resent ± standard error (SEM) in all graphs. ns: P > 0.05, 
*P < 0.05, **P < 0.01, ***P < 0.001.
Results
TDAG8 gene expression is reduced significantly 
in hematologic malignancies in comparison to normal 
immune cells and leukocyte‑rich tissue
Oncomine bioinformatics analysis identified that 
TDAG8 gene expression was reduced in multiple 
forms of blood cancer, including acute myeloid leu-
kemia (AML) (2.2 and 6.1-fold) [31, 32], chronic lym-
phocytic leukemia (CLL) (3.3-, 1.7-, 2.3-, and 2.6-fold) 
(Table 1) [31, 33–35], T-cell acute lymphoblastic leuke-
mia (TCALL) (3.1-fold), B-cell childhood acute lymph-
oblastic leukemia (BCCALL) (2.5-fold), B-cell acute 
lymphoblastic leukemia (BALL) (2.4-fold), pro B-cell 
acute lymphoblastic leukemia (PBALL) (1.3-fold), hairy 
cell leukemia (HCl) (1.9-fold), and T-cell prolympho-
cytic leukemia (TCPLL) (3.9-fold) (Table 1) [31, 33, 36]. 
In addition, TDAG8 gene expression is reduced in sev-
eral lymphomas such as diffuse large B-cell lymphoma 
(DLBCL) (1.4- and 1.9-fold) [33, 34], follicular lym-
phoma (FL) (1.4- and 2.0-fold) [33, 34], pleural effusion 
lymphoma (PEL) (2.7-fold) [33], and Burkitt lymphoma 
(BL) (1.8-fold) [33] (Table  1). Lastly, TDAG8 expres-
sion was found reduced in smoldering myeloma (SM) 
(2.6-fold) (Table  1) [37]. The search in the Oncomine 
Research Premium Edition also revealed various can-
cer cell lines that were resistant to chemotherapeutics 
had reduced TDAG8 gene expression in comparison to 
cancer cell lines that were sensitive to those particular 
chemotherapeutics (Table 2) [38, 39]. A separate analy-
ses of datasets from NCBI GEO revealed that TDAG8 
gene expression is significantly reduced 4.5-fold in AML 
(GEO Series ID GSE9476), 2.9-fold in CLL (GEO Series 
ID GSE22529), 3.6-fold in TCPLL with inv(14)(q11q32) 
(GEO Series ID GSE5788), 2.7-fold in chronic B-cell 
lymphocytic leukemia (CBLL) (GSE26725), 3.0-fold in 
DLBCL (GEO series ID GSE12195), and 2.8-fold in FL 
(GEO series ID GSE12195) (Fig. 1a–e). The same pattern 
was found in various blood cancer cell lines. For exam-
ple, TDAG8 gene expression was reduced 45-fold in 
U937 cells, 8-fold in Ramos cells, undetectable in RPMI 
8226 cells, 625-fold in K562 cells, and 3-fold in Jurkat 
cells in comparison to normal peripheral blood leuko-
cytes (Fig. 2a).
Table 1 TDAG8 gene expression is reduced significantly in blood cancers
CLL chronic lymphocytic leukemia, TCALL T-cell acute lymphoblastic leukemia, BCCALL B-cell childhood acute lymphoblastic leukemia, BALL B-cell acute lymphoblastic 
leukemia, AML acute myeloid leukemia, PBALL pro B-cell acute lymphoblastic leukemia, HCl hairy cell leukemia, TCPLL T-cell prolymphocytic leukemia. TDAG8 gene 
expression is also reduced significantly in DLBCL diffuse large B-cell lymphoma, FL follicular lymphoma, PEL pleural effusion lymphoma, BL Burkitt’s lymphoma, 
SM smoldering myeloma. Rose et al. normal blood cell control: B-lymphocyte (4), CD4+ T-lymphocyte (5), germinal center B-lymphocyte (1), umbilical cord blood 
B-lymphocyte (1), umbilical cord blood T-lymphocyte (1). Hafer et al. normal blood cell control: peripheral blood mononuclear cell (74). Basso et al. normal blood cell 
control: B-lymphocyte (5), centroblast (5), memory B-lymphocyte (5), naive pre-germinal center B-lymphocyte (5), small cleaved follicle center cell (5). Aliz et al. normal 
blood cell control: B-lymphocyte (16), CD4+ T-lymphocyte (6), centroblast (1), germinal center B-lymphocyte (2), lymph node (1), memory B-lymphocyte (3), tonsil (1). 
Stegmaier et al. normal blood cell control: monocyte (3), neutrophil (3). Durig et al. normal blood cell control: CD3+ peripheral blood cell (8). Zhan et al. normal blood 
cell control: bone marrow (22)
Leukemia
Source: Rose et al. Hafer et al.
Cancer CLL TCALL BCCALL BALL AML CLL PBALL
Fold change − 3.25 − 3.13 − 2.497 − 2.372 − 2.236 − 1.706 − 1.317
P 2.3E−7 1.6E−40 8.1E−32 1.1E−26 1.6E−27 1.8E−16 1.6E−4
N 38 174 359 147 542 448 70
Leukemia
Source: Basso et al. Aliz et al. Stegmaier et al. Durig et al.
Cancer CLL HCl CLL AML TCPLL
Fold change − 2.251 − 1.917 − 2.642 − 6.115 − 3.902
P 8.1E−10 1.6E−5 3.4E−5 1.0E−3 1.0E−3
N 12 16 12 9 6
Lymphoma Myeloma
Source: Rose et al. Basso et al. Zhan et al.
Cancer DLBCL FL PEL BL FL DLBCL SM
Fold change − 1.439 − 1.354 − 2.687 − 1.761 − 2.021 − 1.874 − 2.628
P 1.5E−2 3.0E−2 1.0E−3 1.5E−4 1.5E−6 1.3E−6 1.9E−2
N 38 7 9 17 6 32 12
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Table 2 Reduced TDAG8 gene expression correlates with resistance to various chemotherapeutics
Cancer cells of various origins categorized as resistant to specific chemotherapeutics demonstrate a significant reduction in TDAG8 gene expression. The expression 
of TDAG8 in 4 cell lines sensitive to elesclomol is 2.3-fold higher than in 21 cell lines resistant. The expression of TDAG8 in 86 cell lines categorized as sensitive to 
panobinostat is 2.7-fold higher than in 164 cell lines categorized as resistant. The expression of TDAG8 in 71 cell lines categorized as sensitive to irinotecan is 3.2-fold 
higher than in 84 cell lines categorized as resistant. The expression of TDAG8 in 154 cell lines categorized as sensitive to topotecan is 2.2-fold higher than in 124 
cell lines categorized as resistant. The expression of TDAG8 in 6 cell lines categorized as sensitive to navitoclax is 2.4-fold higher than in 12 cell lines categorized as 
resistant. The expression of TDAG8 in 3 cell lines categorized as sensitive to MK2206 is 3.8-fold higher than in 17 cell lines categorized as resistant





















Bcl‑2, Bcl‑XL, and 
Bcl‑w inhibitor
AKT inhibitor
Resistant cell lines 
(Rn)
21 164 84 124 12 17
Sensitive cell lines 
(Sn)
4 86 71 154 6 3
TDAG8 gene 
expression of Sn 
vs Rn
+ 2.3 + 2.7 + 3.2 + 2.2 + 2.4 + 3.8
P 4.8E−2 2.6E−7 4.2E−8 2.9E−10 3.4E−2 7.8E−4
Fig. 1 TDAG8 gene expression is reduced in patients with blood cancers in comparison to healthy donor’s immune cells or leukocyte‑rich tissue. a 
The expression of TDAG8 is reduced 4.5‑fold in CD34+ bone marrow and CD34+ peripheral blood cells isolated from patients with AML (N = 20) 
in comparison to CD34+ bone marrow and CD34+ peripheral blood cells isolated from healthy donors (N = 26). b The expression of TDAG8 is 
reduced 2.9‑fold in CD19+/CD5+ peripheral blood mononuclear cells isolated from patients with CLL (N = 11) in comparison to CD19+/CD5+ 
peripheral blood mononuclear cells isolated from healthy donors (N = 39). c The expression of TDAG8 is reduced 3.6‑fold CD3+ peripheral blood 
cells (N = 8) isolated from patients with TCPLL in comparison to CD3+ peripheral blood cells isolated from healthy donors (N = 6). d The expression 
of TDAG8 is reduced 2.7‑fold in CD19+ peripheral blood lymphocytes isolated from patients with CBLL (N = 6) in comparison to CD19+ peripheral 
blood lymphocytes isolated from healthy donors (N = 11). e The expression of TDAG8 is reduced by 3.0‑fold in DLBCL biopsy samples (N = 73) 
in comparison to B‑lymphocytes isolated from healthy donors (N = 9). The expression of TDAG8 is also reduced by 2.8‑fold in human FL biopsy 
samples (N = 38) in comparison to B‑lymphocytes isolated from healthy donors (N = 9). AML acute myeloid leukemia, CLL chronic lymphocytic 
leukemia, DLBCL diffuse large B‑cell lymphoma, FL follicular lymphoma, TCPLL T‑cell prolymphocytic leukemia with inv(14)(q11q32), CBLL chronic 
B‑cell lymphocytic leukemia. Y‑axis is  Log2 scale. ***P < 0.001
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TDAG8 gene expression provides a disadvantage to blood 
cancer cell growth
As TDAG8 gene expression is commonly downregulated 
in hematological malignancies (Tables 1, 2 and Fig. 1), we 
investigated its function by restoring TDAG8 expression 
in blood cancer cell lines such as U937, Ramos and RPMI 
8226 with low TDAG8 expression. The U937 cell line was 
originally established from a patient with histiocytic lym-
phoma and later found to possess characteristics of acute 
myeloid leukemia (AML) cells [40]. U937 cells were used 
as a model system for this study because the cells have 
features of both lymphoma and leukemia. Proliferation 
of U937 cells transduced with a construct containing the 
human TDAG8 gene (U937/TDAG8) was compared to 
U937 cells transduced with an empty vector (U937/Vec-
tor). The expression level of TDAG8 mRNA in U937/
TDAG8 cells was restored to the similar level as that in 
normal leukocytes (Fig. 2b). Due to the lack of a reliable 
TDAG8 antibody, we were unable to detect TDAG8 pro-
tein expression. Instead, we examined the TDAG8 down-
stream signaling activities and found the phosphorylation 
of CREB was higher in U937/TDAG8 cells than that in 
U937/Vector cells (Additional file  1: Figure S1A), sug-
gesting that restoration of TDAG8 expression augments 
its downstream G protein signaling. Similarly, CREB 
phosphorylation was increased in Ramos/TDAG8 cells 
with the restoration of TDAG8 expression (Additional 
file 1: Figure S1B, C).
Fig. 2 Restoration of TDAG8 gene expression in U937 cells provides a growth disadvantage at physiological pH 7.4 and mildly acidic pH 6.9.  
a Quantitative RT‑PCR demonstrates a reduction of TDAG8 gene expression in U937, ramos, RPMI 8226, K562, and Jurkat cells in comparison to 
peripheral leukocytes pooled from 426 healthy donors. b Quantitative RT‑PCR demonstrates restoration of TDAG8 gene expression in U937 acute 
myeloid leukemia cells following transduction and cell sorting. c Mild acidosis (pH 6.9) increases U937/Vector cell proliferation while severe acidosis 
(pH 6.4) inhibits cell proliferation. Restoring TDAG8 gene expression in U937 cells inhibits cell proliferation in comparison to U937/Vector cells.  
d The expression of the empty MSCV‑IRES‑GFP construct in U937 cells does not substantially affect the U937/Vector cell population percentage in 
comparison to U937/Parental cells at pH 7.4 from day 0 to day 14. e The restoration of TDAG8 gene expression in U937 cells reduces cell growth in 
comparison to U937/Parental cells at physiological pH 7.4. f Restoring TDAG8 gene expression in U937 cells increases apoptosis throughout the cell 
competition assay at pH 7.4. g The expression of the empty MSCV‑IRES‑GFP construct in U937 cells does not substantially affect the U937/Vector 
cell population percentage in comparison to U937/Parental cells at pH 6.9 from day 0 to day 14. h The difference between the U937/TDAG8 cell 
population and the U937/Parental cell population throughout the competition assay at acidic pH 6.9 is greater in comparison to pH 7.4 treatment. 
i Restoring TDAG8 gene expression in U937 cells increases apoptosis throughout the cell competition assay at pH 6.9. Pooled RNA from 426 normal 
peripheral leukocytes was purchased from Clontech Laboratories, Inc. to be used as a control for a healthy immune cell comparison. ns: P > 0.05, 
*P < 0.05, **P < 0.01, ***P < 0.001
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In comparison to U937/Vector cells, U937/TDAG8 
cells proliferated 7% less (47.8% vs. 40.5% proliferat-
ing cells) at physiological pH 7.4 (Fig. 2c). When U937/
Vector cells were treated with pH 6.9, there was a 10% 
increase in cell proliferation in comparison to physio-
logical pH 7.4. However, restoring TDAG8 gene expres-
sion sensitized U937 cells to media buffered to pH 6.9 
and suppressed cell proliferation at pH 6.9 (Fig.  2c). 
Severe acidosis, pH 6.4, significantly reduced cell pro-
liferation in both U937/Vector and U937/TDAG8 cells 
(Fig. 2c).
Next, cell growth competition assays were performed 
to demonstrate negative selection of U937 cells express-
ing the TDAG8 gene. In the cell growth competition 
assay there was a slight change in the U937/Parental-
U937/Vector cell populations (50 ±  5%) after 14  days 
(Fig.  2d). However, the U937/TDAG8 cell population 
was only 30% of the total population of cells in com-
parison to 70% of the U937/Parental cells at pH 7.4 
(Fig.  2e). Quantitative RT-PCR also demonstrated that 
restoration of TDAG8 expression in U937/TDAG8 cells 
reduced the expression of c-myc oncogene on day 0 
and day 14 of the competition assay in comparison to 
the U937/Vector cells (Additional file  1: Figure S2A, 
B). The growth competition assay was also performed 
in medium buffered to mildly acidic pH 6.9. The U937/
TDAG8 cell population was significantly reduced to 
23% of the total population of cells at pH 6.9 (Fig. 2h). 
The U937/Vector and U937/Parental cells showed 
slight changes (50 ±  5%) relative to each other at pH 
6.9 (Fig. 2g). Results were similar when the competition 
assay was performed with the RPMI 8226/Vector and 
RPMI 8226/TDAG8 myeloma cells (Additional file  1: 
Figure S3).
The GFP mean fluorescence value remained stable 
from day 0 to day 14 with little variation in the U937/
Vector cells when co-cultured with the U937/Paren-
tal cells (Additional file 1: Figure S2C). However, U937/
TDAG8 cell GFP mean fluorescence value as an indica-
tor of TDAG8 transgene expression was considerably 
reduced (Additional file 1: Figure S2C). When comparing 
day 0 with day 14 at pH 6.9 there was a 65% reduction 
in GFP mean fluorescence value of U937/TDAG8 cells 
(Additional file 1: Figure S2D).
Annexin V PE/7AAD staining was performed at day 
7 and day 14 of the competition assay to examine U937 
cell apoptosis. It was determined there was a significant 
increase of apoptosis in U937/TDAG8 cells in com-
parison to U937/Parental cells at pH 7.4 and at pH 6.9 
(Fig. 2f, i). Increased apoptosis of U937/TDAG8 cells also 
correlated with an increase in caspase 3, caspase 9, and 
PARP cleavage (Additional file 1: Figure S4).
Restoration of TDAG8 gene expression reduces primary 
tumor growth in severe combined immunodeficient (SCID) 
mice
U937 cells were originally isolated from a patient with 
histiocytic lymphoma and can form solid tumors, which 
are known to be spatially acidic. To determine the effects 
of restoring TDAG8 gene expression on U937 primary 
tumor growth, subcutaneous xenograft experiments 
were performed in SCID mice. A significant inhibition of 
U937/TDAG8 tumor growth was observed throughout 
the experiments (Fig. 3a). In addition, overall tumor mass 
was reduced by ~ 50% in U937/TDAG8 tumors (Fig. 3b). 
Similar trends were found following Ramos/Vector and 
Ramos/TDAG8 lymphoma cell injections into SCID mice 
(Additional file 1: Figure S5). In vivo luminescence imag-
ing was also used to visualize tumor growth over 2 weeks. 
The pattern previously observed in U937/TDAG8 cells, 
i.e. reduced tumor growth, was consistent with the U937/
TDAG8-Luc cells expressing TDAG8 and the luciferase 
marker gene (Fig. 3c).
Decreased c‑myc expression is detected in the tumor zone 
close to necrotic regions
Immunohistochemistry (IHC) of c-myc expression 
revealed that sections nearest necrotic regions of tumors, 
known to be acidic [17], had reduced expression of 
c-myc (Fig.  3d–i). The areas that were investigated for 
low c-myc expression were negative for cleaved PARP 
indicating that intact cells nearest necrotic regions were 
viable (Fig.  3e, g). In addition, it was also revealed that 
invasive cancer cells in the tumor peripheral regions had 
increased expression of c-myc and Ki-67 and were nega-
tive for cleaved PARP (Fig. 3g–i).
Acidosis/TDAG8 reduces c‑myc expression through Gα13/
Rho signaling
IHC analysis of c-myc protein expression revealed that 
U937/TDAG8 tumor cells expressed lower levels of 
c-myc in comparison to U937/Vector control (Fig. 4a, b). 
It was also qualitatively determined that c-myc expres-
sion was undetectable in numerous U937/TDAG8 cells in 
the tumor (Fig. 4b). In comparison, the majority of U937/
Vector cells expressed c-myc at a high level (Fig.  4a). It 
was also determined that restoring TDAG8 gene expres-
sion reduces c-myc protein expression significantly in 
comparison to the U937/Vector control cells at physi-
ological pH 7.4 in vitro (Fig. 4c, d). In addition, activation 
of TDAG8 by extracellular acidification, representing 
similar conditions as the tumor microenvironment, fur-
ther reduces c-myc expression in comparison to pH 7.4 
treatment and to the U937/Vector controls (Fig.  4c, d). 
These observations are consistent with previous studies 
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showing that TDAG8 has some constitutive activities at 
the physiological pH and is fully activated under acidic 
pH [41].
Following inhibition of Gα13 signaling by the p115 
RGS construct [28, 29], Western blot analysis determined 
that c-myc expression was restored in the U937/TDAG8 
cells after treatment with media buffered to pH 7.4 and 
pH 6.4 (Fig.  4e, f ). These results reveal that Gα13 sign-
aling is central for TDAG8-mediated c-myc inhibition 
at physiological pH 7.4 and acidic pH 6.4. The activa-
tion of Rho GTPases with CN01, downstream from the 
p115-RGS Gα13 inhibition, reduced the expression of 
c-myc, indicating that Gα13/Rho signaling in U937 cells 
inhibits c-myc expression (Fig. 4e, f ). Similar results were 
found for caspase 3, caspase 9, and PARP cleavage fol-
lowing inhibition of Gα13 signaling and activation of Rho 
(Additional file 1: Figure S6). Therefore, the data suggests 
TDAG8 exerts its growth inhibitory effects through acti-
vation of Gα13/Rho signaling in U937 cells.
Restoration of TDAG8 gene expression in U937 cells 
reduces cell attachment and migration correlating 
with altered focal adhesion dynamics
Restoration of TDAG8 gene expression reduced the abil-
ity for U937 cells to attach to Matrigel at physiological pH 
7.4 by more than 50% (Fig. 5a). Activation of TDAG8 by 
extracellular acidosis reduced U937 cell attachment even 
further demonstrating the anti-metastatic capabilities 
of TDAG8 (Fig.  5a). U937 cell attachment to a HUVEC 
monolayer was also investigated revealing a reduction in 
U937/TDAG8 cell attachment to endothelial cells at phys-
iological pH 7.4 and acidic pH 6.4 (Additional file 1: Fig-
ure S7A). However, overall cell attachment to a HUVEC 
monolayer was increased at acidic pH 6.4 likely due to the 
effects of acidosis on endothelial cell-mediated attach-
ment [42]. It was also determined that U937/TDAG8-Luc 
cells exhibited less cell migration towards the chemoat-
tractant SDF-1α in comparison to U937/Vector-Luc 
cells (Fig. 5b). In addition, treatment with pH 6.4 further 
Fig. 3 Restoring TDAG8 gene expression in U937 cells reduces primary tumor growth in SCID mice. a U937/TDAG8 tumor growth was signifi‑
cantly reduced in comparison to U937/Vector tumors from day 4 to necropsy (N = 14). b U937/TDAG8 tumor mass was reduced significantly in 
comparison to U937/Vector tumors following necropsy. c In vivo imaging of 3 mice injected with U937/Vector‑Luc or U937/TDAG8‑Luc cells 6 days 
after injection. Scale Bar = 2 cm. d, e Immunohistochemistry of c‑myc d and cleaved PARP e in U937/Vector tumors demonstrating regions near‑
est necrotic areas display reduced c‑myc oncogene expression while still live. f–i Hematoxylin and eosin staining (f) and immunohistochemistry 
of U937/Vector tumors demonstrating invasive peripheral regions of U937 tumors display increased proliferation by c‑myc (h) and Ki67 (i) while 
demonstrating less apoptosis, cleaved PARP (g). N necrotic. White lines indicate areas adjacent to necrotic zones. Black lines indicate tumor cells that 
are invasive correlating with higher c‑myc and Ki67 expression. Black arrowheads indicate single tumor cells that demonstrate reduced or no c‑myc 
expression. *P < 0.05, **P < 0.01, ***P < 0.001
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Fig. 4 Restoration of TDAG8 gene expression reduces c‑myc oncogene expression through Gα13/Rho signaling. a IHC demonstrates the majority 
of cells within the U937/Vector tumors away from necrotic or heterotypic areas are positive for c‑myc expression as indicated by DAB chromogen 
(N = 5). b There were less cells within the U937/TDAG8 tumors away from necrotic or heterotypic areas positive for c‑myc expression as indicated 
by DAB chromogen. Arrowheads indicate cells not expressing c‑myc. Observed in at least 3, 5 µm sections of 5 different tumors for each experi‑
mental group. c Restoration of TDAG8 in U937 cells reduces c‑myc expression in response to treatment with media buffered to physiological pH 7.4 
and acidic pH 6.4. d Quantification of c‑myc Western blot data displaying the significant inhibition of c‑myc mediated by acidosis and TDAG8 gene 
expression. e, f Gα13/Rho signaling is responsible for a TDAG8 mediated inhibition of c‑myc expression. *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 5 TDAG8 gene expression reduces U937 cell attachment and migration. a Restoration of TDAG8 gene expression inhibits U937 cell attachment 
to matrigel. b U937 cell migration towards SDF1‑α is inhibited by TDAG8 gene expression at pH 7.4 and pH 6.4. c Acidosis and restoration of TDAG8 
gene expression reduces phosphorylation of paxillin at Y118 in U937 cells. d Quantification of paxillin phosphorylation at Y118 reveals a significant 
reduction in U937/TDAG8‑luc cells at pH 7.4 and 6.4. ns: P > 0.05, *P < 0.05, P < 0.01, ***P < 0.001
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reduced the migration of U937/TDAG8-Luc cells in com-
parison to the U937/Vector-Luc cells (Fig.  5b). This was 
also observed in the U937 cells that were transduced with 
the GFP construct (Additional file 1: Figure S7B).
Increased activity of focal adhesion proteins such as 
focal adhesion kinase (FAK) and paxillin have been cor-
related with poor patient survival and increased malig-
nancy of blood and other cancers [43–48]. We found 
that restoring TDAG8 gene expression in U937 cells sig-
nificantly inhibited the phosphorylation of paxillin Y118 
at pH 7.4 and pH 6.4 (Fig.  5c, d), suggesting a reduced 
activity of the FAK/paxillin pathway [49, 50]. In addition, 
when treated with media buffered to pH 6.4 the phos-
phorylation of paxillin Y118 was reduced in comparison 
to the pH 7.4 treatment groups (Fig. 5c, d).
Restoration of TDAG8 gene expression in U937 cells 
reduces metastasis in SCID mice following tail vein 
injections
Overall, the in vivo imaging of SCID mice was not sensi-
tive enough to visualize micro-metastasis of tumor cells 
(Fig.  6a–e). However, larger nodules and tumors were 
easily visualized (Fig. 6a). Metastasis of U937/Vector cells 
to the lymph node, bone of the limb, and other organs in 
SCID mice was detected by IVIS luminescence imaging 
(Fig. 6a; Additional file 1: Figure S7C). To further quan-
tify metastasis, the mouse lungs were analyzed using an 
anti-human nucleoli antibody specific for human cells 
(Fig. 6b–e). The results indicate the severity of U937 cell 
metastasis to the lung of SCID mice was significantly 
reduced by restoring TDAG8 expression (Fig. 6f ).
Fig. 6 Restoration of TDAG8 gene expression reduces U937 cell metastasis in SCID mice. In vivo luminescence imaging identified larger tumors but 
was not sensitive enough to identify micro metastasis in SCID mice. a IVIS luminescence imaging. Scale bar = 2 cm. b Normal mouse spleen section 
with negative staining demonstrating the specificity of the anti‑human nucleoli antibody. c Tumor metastasis in the lymph node was positive for 
human nucleoli. d, e Hematoxylin and eosin staining and IHC of the human nucleoli antibody was used to identify nuclear localization of the anti‑
body signals of U937/Vector tumor cells in the lung of SCID mice. f Analysis of SCID mice lungs following IHC of human nucleoli reveals a significant 
reduction in metastasis. Mice with no metastasis detected were given a score of 0. Mice with < 2 average metastatic lesions in each 5 µm section of 
the lung were given a score of 1, from 2 to 5 average metastatic lesions were given a score of 2, from 6 to 10 average metastatic lesions were given a 
score of 3, and from 11 or more average metastatic lesions were given a score of 4. In addition, lesions that were larger than 20 cells or large enough 
to see with the IVIS Lumina XR unit was given a 4. For each experimental group injected with either U937/Vector‑Luc or U937/TDAG8‑Luc cells the 
individual scores were added up and averaged to give a metastasis score. The scoring system consisted of analyzing a total of 6 sections of lung for 
each mouse injected. Every section was separated by at least 20 µm of tissue to give representative sections of various areas of the lung. **P < 0.01
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Discussion
The effect of extracellular acidosis on cancer progres-
sion is complex; therefore it is important to understand 
the cancer cell biological response to it [13]. In this study 
it was determined that diverse extremities of extracel-
lular acidosis had differential effects on cellular prolif-
eration (Fig. 2c–e, g, h). It was clearly demonstrated that 
mild extracellular acidosis, pH 6.9, increased U937 cell 
proliferation while severe acidosis, pH 6.4, repressed it 
(Fig. 2c). In addition, this report evaluated the effects of 
tumor acidosis on c-myc oncogene expression in  vivo. 
In tumor sections nearest necrotic regions, known to be 
acidic [17], c-myc oncogene expression was reduced sig-
nificantly in live tumor cells (Fig.  3d–i). However, inva-
sive cancer cells that were invading new tissue, devoid 
of blood vessels and nutrients, did not follow this pat-
tern (Fig.  3d–i). Conversely, invasive tumor cells had 
increased expression of c-myc and Ki-67 signifying they 
are actively proliferating and invasive despite extracel-
lular acidosis and nutrient deprivation (Fig.  3d–i). The 
discovered pattern of tumor cell invasiveness in harsh 
extracellular conditions concurrently associating with 
increased cell proliferative markers is similar to an acid 
resistant phenotype described previously [17, 18]. Impor-
tantly, understanding that extracellular acidosis reduces 
c-myc oncogene expression in some tumor cells while 
not in others provides an original understanding for the 
heterotypic and spatial tumor cell response to extracellu-
lar acidosis. To understand how tumor cells sense extra-
cellular acidosis the proton sensing G-protein coupled 
receptor TDAG8 was investigated.
The data provided in this study indicates that TDAG8 
gene expression is suppressive for U937 cell malig-
nancy. It was discovered that TDAG8 gene expression is 
reduced in the majority of blood cancers in comparison 
to normal immune cells or leukocyte-rich tissue (Table 1 
and Fig. 1). In addition, higher expression of the TDAG8 
gene correlates with increased sensitivity toward various 
chemotherapeutics (Table 2). Using U937 acute myeloid 
leukemia cells as a model system TDAG8 gene expres-
sion was restored to a normal physiological level to test 
the hypothesis that TDAG8 gene expression provides a 
disadvantage for blood cancer cell malignancy. Restor-
ing TDAG8 gene expression in U937 cells reduced cell 
proliferation in  vitro and tumor growth and metastasis 
in vivo (Figs. 2, 3, 6). The ability for TDAG8 gene expres-
sion to provide a disadvantage for U937 cell proliferation, 
tumor growth, and metastasis confirmed that TDAG8 
gene expression provides a disadvantage for blood can-
cer progression. Similar tumor suppressive functions of 
TDAG8 were observed in other blood cancer cells such 
as Ramos Burkitt lymphoma and RPMI 8226 multi-
ple myeloma cells (Additional file 1: Figures S3 and S5). 
Moreover, TDAG8’s inherent ability to reduce c-myc 
expression at physiological pH 7.4 and acidic pH 6.4 is 
central (Fig. 4a–c) [23]. This is consistent with previous 
results demonstrating that TDAG8 exhibits constitu-
tive activity at physiological pH and is further activated 
at acidic pH [41]. Moreover, the results from this report 
indicate that the inhibitory effects of acidosis on c-myc 
oncogene expression are partially due to TDAG8-medi-
ated Gα13/Rho signaling (Fig.  4e–f). This idea aligns 
with recent reports that demonstrate Gα13/Rho signal-
ing suppresses oncogenesis and acts as a tumor suppres-
sor in lymphoma [51–53]. Overall, it is hypothesized in 
this report that extracellular acidosis provides a selective 
pressure against cancer cells, which modulates clonal 
cell evolution. Moreover, TDAG8 is a proton sensor that 
plays an important role in this process, which has impor-
tant implications for blood cancer progression as well as 
cancer cell clonal evolution parallel to extracellular aci-
dosis found within the tumor microenvironment.
TDAG8 has been reported to have a diverse repertoire 
of pro- and anti-oncogenic effects that are cancer type 
and context dependent [22–24, 54–57]. These seemingly 
conflicting observations can potentially be explained by 
TDAG8 downstream signaling—the Gα13 G-protein/
Rho GTPase signaling. Studies have shown that Gα13 
and Rho GTPases can have pro-oncogenic or anti-
oncogenic effects in a cancer type and context depend-
ent manner [51–53, 58–61]. Gα13 and Rho GTPases 
exhibit pro-tumorigenic effects in various types of epi-
thelial cancers [58–60], but have anti-tumorigenic effects 
in hematological malignancies [51–53]. The differential 
effects of Gα13/Rho GTPases may contribute to the anti-
oncogenic effects of TDAG8 in hematological malignan-
cies and the pro-oncogenic effects in other cancer types 
[22–24, 54–57]. To better understand the involvement 
of TDAG8 in various tumor types, we performed addi-
tional bioinformatic analyses of the Oncomine database 
to evaluate TDAG8 (GPR65) expression in cancerous and 
normal tissues [62–69]. The results show that TDAG8 
is over-expressed in several types of epithelial tumors, 
including brain tumor, kidney cancer, and head and neck 
cancer when compared to their normal tissue counter-
parts (Additional file  2: Table S1). Methodologically, 
however, cautions should be taken when interpreting the 
expression profile of TDAG8 in epithelial tumors. RNA 
for gene expression analysis was isolated from whole 
tumor tissues [62–69]. As a result, it is unclear whether 
the over-expression of TDAG8 is derived from epithe-
lial cancer cells or from infiltrated leukocytes which are 
known to highly express TDAG8 [20, 21, 70, 71]. Also, 
interestingly, TDAG8 expression is either not changed 
[54] or down-regulated in lung cancer samples when 
compared to normal lung tissues (Additional file 2: Table 
Page 12 of 14Justus et al. J Transl Med  (2017) 15:204 
S1). Taken together, the expression pattern of TDAG8 in 
epithelial tumors varies, probably complicated by infil-
trated leukocytes that highly express TDAG8 [20, 21, 70, 
71]. In contrast, TDAG8 expression is consistently down-
regulated in hematological malignancies when compared 
to normal blood cells and tissues (Table  1 and Fig.  1). 
Moreover, functional results from this study, together 
with previous studies [22, 23], suggest that TDAG8 
acts as a contextual tumor suppressor in hematological 
malignancies.
Conclusions
In summary, this study reveals that the acid-sensing 
receptor TDAG8 (GPR65) is down-regulated in multi-
ple types of hematological malignancies, including leu-
kemia, lymphoma and multiple myeloma. Our in  vitro 
and in  vivo results demonstrate that TDAG8 functions 
as a tumor suppressor in hematological malignancies 
and sensitizes blood cancer cells to acidotic stress in 
the microenvironment. Mechanistically, the TDAG8-
mediated Gα13/Rho signaling results in the reduction 
of c-myc oncogene expression which may contribute to 
TDAG8 tumor suppressive effects. This observation is 
also concordant with the tumor suppressor function of 
Gα13/Rho in hematological malignancies [51–53]. Our 
findings in this study suggest that potentiation of the 
TDAG8 (GPR65) receptor pathway may be exploited as 
a potential therapeutic approach for the treatment of 
hematological malignancies.
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of TDAG8 gene expression reduces c‑myc oncogene expression at the 
mRNA level in U937 cells. (C) Over 14 days U937/TDAG8 GFP expres‑
sion is reduced at physiological pH 7.4 while U937/Vector GFP is stable. 
(D) Reduction of U937/TDAG8 GFP expression is further augmented by 
activation of TDAG8 with acidic pH 6.9 treatment while the U937/Vector 
GFP is stable. ns: P > 0.05, *P < 0.05, ***P < 0.001. Figure S3. Restora‑
tion of TDAG8 gene expression in RPMI 8226 myeloma cells inhibits cell 
proliferation. (A) The empty vector does not substantially affect RPMI 
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reduces RPMI 8226 cell proliferation at physiological pH 7.4 in comparison 
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tially affect RPMI 8226 cell proliferation at acidic pH 6.9 in comparison to 
the RPMI 8226 parental cells. (D) Restoration of TDAG8 gene expression 
significantly reduces RPMI 8226 cell growth at acidic pH 6.9 in comparison 
to the RPMI 8226 parental cells. ***P < 0.001. Figure S4. Restoration of 
TDAG8 gene expression increases apoptosis signaling. (A, B) Restoration 
of TDAG8 gene expression stimulates cleaved caspase 3 in U937 cells at 
physiological pH 7.4 and acidic pH 6.4. (A and C) Restoration of TDAG8 
gene expression increases cleaved caspase 9 in U937 cells at physiological 
pH 7.4. (A and D) Restoration of TDAG8 gene expression increases cleaved 
PARP in U937 cells at acidic pH 6.4. ns: P > 0.05, *P < 0.05. Figure S5. 
Restoration of TDAG8 gene expression in Ramos lymphoma cells reduces 
primary tumor growth in SCID mice. (A) Representative image of a mouse 
subcutaneously injected with Ramos/Vector (left flank) and Ramos/TDAG8 
(right flank) cells. (B) Restoration of TDAG8 in Ramos cells significantly 
delays primary tumor growth in SCID mice starting day 9 after injection. 
(C) Restoring TDAG8 gene expression in Ramos cells moderately reduces 
overall tumor mass after necropsy on day 21. (D) Representative image 
of Ramos/Vector and Ramos/TDAG8 tumors excised from SCID mice. ns: 
P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001. Figure S6. TDAG8 stimulates 
apoptotic signaling through Gα13/Rho signaling. (A, B) Inhibition of Gα13 
signaling in U937/TDAG8 cells reduces cleaved caspase 3 and activa‑
tion of Rho in U937/TDAG8 cells stimulates cleaved caspase 3. (A and C) 
Inhibition of Gα13 signaling in U937/TDAG8 cells reduces cleaved caspase 
9 and activation of Rho in U937/TDAG8 cells stimulates cleaved caspase 
9. (A and D) Inhibition of Gα13 signaling in U937/TDAG8 cells reduces 
cleaved PARP and activation of Rho in U937/TDAG8 cells stimulates 
cleaved PARP. ns: P > 0.05, *P < 0.05. Figure S7. Restoration of TDAG8 
gene expression in U937 cells reduces attachment to a HUVEC monolayer 
and reduces migration toward a chemoattractant. (A) Restoration of 
TDAG8 gene expression reduces overall U937 cell attachment to a HUVEC 
monolayer while extracellular acidosis increases cell attachment. (B) Resto‑
ration of TDAG8 gene expression significantly reduces U937 cell migration 
toward a chemoattractant (SDF‑1α) while extracellular acidosis reduces 
overall U937 cell migration. (C) In vivo imaging of a SCID mouse injected 
with U937/Vector‑Luc cells that presented with hind limb paralysis and 
metastasis throughout the body. *P < 0.05, **P < 0.01, ***P < 0.001.
Additional file 2: Table S1. TDAG8 gene expression in various cancer 
types compared to normal tissues.
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